~~<i id='6E3E41B50A'><strike id='6E3E41B50A'><tt id='6E3E41B50A'><pre id='6E3E41B50A'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：hotspot 2025-09-28 06:03:48 Page View：43

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ProMED sees offers of support, but its future remains unclear
Next article： The high cost of giving birth even with insurance

explore

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Judge rejects Trump's request to move Stormy Daniels hush

0:31FormerPresidentDonaldTrumpspeaksattheConservativePoliticalActionConference,CPAC2023,March4,2023,

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Divers poised to search for children washed away in Pennsylvania flash flood

1:17FloodingisseenhereinNewtownPennsylvaniaaftersomeseverestorms,July16,2023.ABCNewsDiverswerepoised